ResMed Offloads MatrixCare Business in $708 Mn Transaction
Synopsis
Key Highlights ResMed's MatrixCare sale to Frazier will see MatrixCare sold for US$490 million (A$707.5 million). Closing is anticipated in the first quarter of FY27. The divestiture furthers ResMed's 2030 strategy and will continue…
Key Highlights
- ResMed's MatrixCare sale to Frazier will see MatrixCare sold for US$490 million (A$707.5 million).
- Closing is anticipated in the first quarter of FY27.
- The divestiture furthers ResMed's 2030 strategy and will continue to underwrite the company's long-term capital allocation plans.
ResMed has entered into a commitment to sell its MatrixCare business for US$490 million (A$707.5 million) to Seattle-based private equity firm Frazier Healthcare Partners, with the deal to be settled in FY27’s first quarter.
ResMed Refocuses on Sleep Health
ResMed MatrixCare was sold for $490 million which fits the company-wide 2030strategy. Resmed closes down low organizational execution views around sleep health and digital well being with maximum enhancements to become a frontrunner in high-growth openings across images of earlier wellbeing.
What the Sale Includes
The ResMed ASX RMD divestment also includes MatrixCare and associated software interests, including Healthcare First and Citus.
These businesses collectively deliver software solutions to over 15,000 providers in skilled nursing, senior living, and home health and hospice care.
ResMed CEO stated that the divestment was in line with its strategy of focusing on businesses where it sees the most opportunity to maximise innovation and optimise outcomes for patients and long-term shareholder value.
Source: Capital Brief
Follow Inspirepreneur Magazine for daily global business news
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
